Resources for the attention of patients with breast cancer in Mexico

Bargalló-Rocha, Enrique; Ruvalcaba-Limón, Eva; Quintero-Beuló, Gregorio; Reséndiz-Colosia, Jaime Alonso; Salas-González, Efraín; Serrano-Olvera, Juan Alberto; Silva-Juan, Alejandro; Maffuz-Aziz, Antonio; Figueroa-Martínez, Pedro; Villalobos-Valencia, Ricardo; Villarreal-Garza, Cynthia; Cardona-Huerta, Servando; Serrano-Ortiz, Rodrigo; Rodríguez-Trejo, Amelia; Barragán-Curiel, Adolfo Eduardo; Rodríguez-Cuevas, Sergio

doi:10.24875/j.gamo.19000258

Services on Demand

Journal

Article

Indicators

Cited by SciELO
Access statistics

Gaceta mexicana de oncología

On-line version ISSN 2565-005XPrint version ISSN 1665-9201

Abstract

BARGALLO-ROCHA, Enrique et al. Resources for the attention of patients with breast cancer in Mexico. Gac. mex. oncol. [online]. 2019, vol.18, n.3, pp.121-126. Epub June 13, 2022. ISSN 2565-005X. https://doi.org/10.24875/j.gamo.19000258.

Multicenter studies on breast cancer require inter-institutional collaboration, resources and specialized personnel. In Mexico, many institutions provide these services, but their information is not accessible; to mitigate it, the Mexican Society of Oncology formed the Mexican Cooperative Research Groups in Oncology.

Objective:

To describe the infrastructure, personnel and activities of hospitals with care of patients with breast cancer in Mexico.

Methods:

A survey was conducted to 30 breast cancer specialists about resources and services of their institutions.

Results:

13 (43.3%) specialists answered the survey, 38.5% of Seguro Popular, 23.1% of Instituto Mexicano del Seguro Social, and 38.4% of other institutions, with a median of 300 (50-950) new cases per year. All the institutions have oncological surgery, breast radiology, palliative care, pathology, nutrition and multidisciplinary sessions. All have ultrasound with breast transducer, 92.3% digital mammography, and 53.8% tomosynthesis and/or magnetic resonance. They do sentinel lymph node detection with dye (92.3%) or radionuclide (61.5%). Tamoxifen, aromatase inhibitors and trastuzumab are available in 92.3%, and other target therapies in < 40%. Genetic signatures are done in 21.3% and 61.5% analysis of hereditary cancer.

Conclusions:

The institutional capacity to participate in multicenter studies is heterogeneous; the few resources in several institutions limit their inclusion to studies of breast cancer.

Keywords : Infrastructure; Services; Quality of attention; Breast cancer; Mexico.

· abstract in Spanish · text in Spanish